Navigation Links
Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
Date:5/15/2012

WORCESTER, Mass. and TORONTO, May 15, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT), in anticipation of the transition into pivotal Phase III trials, is pleased to announce today that the expertise of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., has been expanded by the addition of two globally recognized experts in clinical trial research and immuno-therapeutic treatments of breast cancer:

Dr. Kathy D. Miller, M.D.
Indiana University School of Medicine Melvin and Bren Simon Cancer Center
Department of Medicine, Division of Hematology and Oncology

Dr. Miller's career combines both laboratory and clinical research in breast cancer.  She has served as co-chair of the Hoosier Oncology Group Breast Committee since early 2002 and became co-chair of the Eastern Cooperative Oncology Group Breast Core Committee in 2010.  In these roles, she has worked with community oncologists to develop trials that combine clinical and biologic endpoints, yet remain feasible in non-academic settings.  Dr. Miller first honed her ability to coordinate multi-center trials as principal investigator for E2100, the first phase III trial to confirm the benefits of anti-angiogenic therapy in patients with metastatic breast cancer.  Dr. Miller currently leads E5103, an international phase III trial investigating anti-angiogenic therapy in the adjuvant setting.

Dr. Miller received her MD in 1991 from the Johns Hopkins School of Medicine in Baltimore, MD.  Dr. Miller completed internal medicine training at Hopkins, then returned to her native Midwest for fellowship training in hematology and oncology at Indiana University, serving as Chief Fellow in 1997.  She returned to Indiana University in 1999, attaining the rank of Associate Professor and Sheila D Ward Scholar in 2005.

Dr. Hope S. Rugo, M.D. 
University of Calif
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... LAVAL, Quebec , November 21, 2014 ... Martensen wechselt als Chief Commercial Officer zu KLOX ... zum SVP der Unternehmensentwicklung und Chief Financial Officer bestellt ... in Europa mit der Vermarktung seines jüngst zugelassenen Behandlungssystems ... Technologies Inc. ("KLOX" bzw. das "Unternehmen") ist sehr erfreut, ...
(Date:11/21/2014)... November 20, 2014 Offering a complete ... Sartorius Entris Balance promotion . The Sartorius Entris Balance ... durable, high accuracy, and easy-to-maintain balance entry level balance. ... It was designed to help customer’s bridge the gap ... balance that is very durable. Sartorius is the second ...
(Date:11/21/2014)... November 20, 2014 The November 2014 ... as an open access journal featuring the following articles:, ... proteins to preserve photoresponsiveness in the retina , ... in situ hybridization using chromogenic substrates in zebrafish , ... RNA, and protein electrophoresis , Nuclear LC3-positive ...
(Date:11/21/2014)... 2014 2014 Deep Research Report ... in-depth research report on the transformer market. The ... application, and industry chain structure as well as ... analysis, including China’s domestic market as well as ... situation analysis. The report also covers information on ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3
... Jan. 2 Nektar,Therapeutics, (Nasdaq: NKTR ) President ... at the upcoming JPMorgan 26th Annual Healthcare,Conference at the ... January 8, 2008, at 4:30 p.m. Pacific Time., ... and slideshow,webcast through a link posted on the Investor ...
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it has ... Food and Drug Administration (FDA) requesting approval of,TREANDA(R) ... patients,with indolent B-cell non-Hodgkin,s lymphoma (NHL) who have ... rituximab-containing,regimen. According to the National Cancer Institute, an ...
... MYL ) today,announced that Mylan Pharmaceuticals Inc. ... Drug Administration (FDA) for its Abbreviated New Drug,Application ... Balsalazide Disodium Capsules are the generic version of ... approximately,$130.9 million for the 12 months ending Sept. ...
Cached Biology Technology:Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
(Date:11/10/2014)... began appearing on U.S. store shelves in early 2010, ... since. The small packets can be tossed into a ... liquid or powder. The convenience, though, has come with ... researchers at Nationwide Children,s Hospital found that from 2012 ... 17,230 children younger than 6 years of age swallowing, ...
(Date:11/7/2014)... Florida , November 6, 2014 ... authentication for better mobile security revolutionizing online transactions.  Companies in ... Alibaba Holdings Ltd. (NYSE: BABA ), Google Inc. ... MSFT ), eBay Inc. (NASDAQ: EBAY ) and ... NXTD and NXTDW), a biometric authentication company focused ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... Using sophisticated detection methods, researchers at the Saint Louis ... molecular mechanism by which the HIV virus infects, or ... drug treatments for HIV. , Although scientists theorized that ... inside a healthy cell in order to infect it, ...
... is shaped by evolution through environmental pressures and ... other ways very similar might respond to their ... differently, using photoreceptors that are attuned to particular ... of closely-related fish species inhabiting the Great Lakes ...
... treatment for stroke has taken a major step forward following ... The University of Manchester have shown in laboratory studies that ... injury and death. , The team, led by Professor Nancy ... of the first small trial of IL-1ra in patients, which ...
Cached Biology News:SLU researchers uncover direct evidence on how HIV invades healthy cells 2Multiple genes permit closely related fish species to mix and match their color vision 2Stroke treatment a step closer after trial 2
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Profilin-1/2 (FL-140)...
Biology Products: